USPSTF draft backs breast-cancer prevention drugs when risk is high

04/15/2013 | Reuters · DailyRx.com

The U.S. Preventive Services Task Force released draft guidelines urging providers to discuss with their female patients the benefits and dangers of drugs that could reduce breast cancer risks. Providers should offer tamoxifen or raloxifene in cases of increased risk of breast cancer and when side effects appear unlikely. A research analysis performed by USPSTF and reported in the Annals of Internal Medicine found that tamoxifen and raloxifene reduced women's breast cancer risk by up to 56%.

View Full Article in:

Reuters · DailyRx.com

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
Director, Payer Marketing
Avalere Health
Washington, DC
Actuary
Meridian Health Plan
Detroit, MI
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Childre's Health Plan
Houston, TX